Operational Costs Compared: SG&A Analysis of Genmab A/S and Galapagos NV

A Decade of SG&A Evolution: Genmab A/S vs. Galapagos NV

In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Genmab A/S and Galapagos NV have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S has seen a staggering increase of over 4,000% in SG&A expenses, peaking at approximately 3.3 billion in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Galapagos NV's SG&A expenses grew by about 940%, reaching a high of 239 million in 2022, before a notable dip in 2023. This fluctuation suggests a strategic recalibration in their operational spending. The data underscores the dynamic nature of financial strategies in the biotech sector, where companies must balance growth with cost management to maintain competitive advantage.